The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program

Overview

Journal J Prev Alzheimers Dis

Specialty Neurology

Date 2021 Jun 8

PMID 34101785

Citations 4

Authors

T Berkness

M C Carrillo

R Sperling

R Petersen

P Aisen

C Flournoy

H Snyder

R Raman

J D Grill

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's Disease and Related Dementias (ADRD) clinical trials require multidisciplinary expertise in medicine, biostatistics, trial design, biomarkers, ethics, and informatics.

Objectives: To provide focused interactive training in ADRD clinical trials to a diverse cadre of investigators.

Design: The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) is a novel multidisciplinary clinical trial training program funded by the National Institute on Aging and the Alzheimer's Association with two educational tracks. The Professionals track includes individuals who fill a broad variety of roles including clinicians, study coordinators, psychometricians, and other study professionals who wish to further their knowledge and advance their careers in ADRD trials. The Fellowship track includes current and future principal investigators and focuses on the design, conduct and analysis of ADRD clinical trials.

Setting: The 2020 inaugural iteration of IMPACT-AD was held via Zoom.

Participants: Thirty-five trainees (15 Fellowship track; 20 Professionals track) were selected from 104 applications (34% acceptance rate). Most (n=25, 71%) identified as female. Fifteen (43%) were of a non-white race; six (18%) were of Hispanic ethnicity; eight (23%) indicated they were the first person in their family to attend college.

Measurements: Participants completed daily evaluations as well as pre- and post-course assessments of learning.

Results: Across topic areas, >90% of trainees evaluated their change in knowledge based on the lectures as "very much" or "somewhat increased." The mean proportion correct responses in pre- and post-course assessments increased from 55% to 75% for the Professionals track and from 54% to 78% for the Fellowship track.

Conclusions: IMPACT-AD successfully launched a new training opportunity amid a global pandemic that preliminarily achieved the goals of attracting a diverse cohort and providing meaningful training. The course is funded through 2025.

Citing Articles

Accelerating Alzheimer's therapeutic development: The past and future of clinical trials.

Boxer A, Sperling R Cell. 2023; 186(22):4757-4772.

PMID: 37848035 PMC: 10625460. DOI: 10.1016/j.cell.2023.09.023.

Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report.

Raman R, Aisen P, Carillo M, Detke M, Grill J, Okonkwo O J Prev Alzheimers Dis. 2022; 9(3):388-392.

PMID: 35841239 PMC: 9098373. DOI: 10.14283/jpad.2022.50.

Early-stage Alzheimer disease: getting trial-ready.

Aisen P, Jimenez-Maggiora G, Rafii M, Walter S, Raman R Nat Rev Neurol. 2022; 18(7):389-399.

PMID: 35379951 PMC: 8978175. DOI: 10.1038/s41582-022-00645-6.

A cultural approach to dementia - insights from US Latino and other minoritized groups.

Vila-Castelar C, Fox-Fuller J, Guzman-Velez E, Schoemaker D, Quiroz Y Nat Rev Neurol. 2022; 18(5):307-314.

PMID: 35260817 PMC: 9113534. DOI: 10.1038/s41582-022-00630-z.

References

Watson J, Ryan L, Silverberg N, Cahan V, Bernard M . Obstacles and opportunities in Alzheimer's clinical trial recruitment. Health Aff (Millwood). 2014; 33(4):574-9. PMC: 4167360. DOI: 10.1377/hlthaff.2013.1314. View

Cummings J, Tractenberg R, Gamst A, Teri L, Masterman D, Thal L . Regression to the mean: implications for clinical trials of psychotropic agents in dementia. Curr Alzheimer Res. 2005; 1(4):323-8. PMC: 4371726. DOI: 10.2174/1567205043332027. View

Dilworth-Anderson P, Thaker S, Burke J . Recruitment strategies for studying dementia in later life among diverse cultural groups. Alzheimer Dis Assoc Disord. 2005; 19(4):256-60. DOI: 10.1097/01.wad.0000190803.11340.66. View

Geda Y, Schneider L, Gitlin L, Miller D, Smith G, Bell J . Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement. 2013; 9(5):602-8. PMC: 3766403. DOI: 10.1016/j.jalz.2012.12.001. View

Elliott C . Together We Make the Difference: National Strategy for Recruitment and Participation in Alzheimer's and Related Dementias Clinical Research. Ethn Dis. 2020; 30(Suppl 2):705-708. PMC: 7683031. DOI: 10.18865/ed.30.S2.705. View

Grill J, Karlawish J . Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther. 2010; 2(6):34. PMC: 3031880. DOI: 10.1186/alzrt58. View

Olin J, Dagerman K, Fox L, Bowers B, Schneider L . Increasing ethnic minority participation in Alzheimer disease research. Alzheimer Dis Assoc Disord. 2002; 16 Suppl 2:S82-5. DOI: 10.1097/00002093-200200002-00009. View

Sperling R, Aisen P, Beckett L, Bennett D, Craft S, Fagan A . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):280-92. PMC: 3220946. DOI: 10.1016/j.jalz.2011.03.003. View

Fleisher A, Raman R, Siemers E, Becerra L, Clark C, Dean R . Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008; 65(8):1031-8. PMC: 2682361. DOI: 10.1001/archneur.65.8.1031. View

10.

Cummings J, Doody R, Clark C . Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007; 69(16):1622-34. DOI: 10.1212/01.wnl.0000295996.54210.69. View

11.

Arean P, Gallagher-Thompson D . Issues and recommendations for the recruitment and retention of older ethnic minority adults into clinical research. J Consult Clin Psychol. 1996; 64(5):875-80. DOI: 10.1037//0022-006x.64.5.875. View

12.

Getz K, Faden L . Racial disparities among clinical research investigators. Am J Ther. 2008; 15(1):3-11. DOI: 10.1097/MJT.0b013e31815fa75a. View

13.

van Dyck C, Nygaard H, Chen K, Donohue M, Raman R, Rissman R . Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2019; 76(10):1219-1229. PMC: 6646979. DOI: 10.1001/jamaneurol.2019.2050. View

14.

Milne R, Karlawish J . Expanding engagement with the ethical implications of changing definitions of Alzheimer's disease. Lancet Psychiatry. 2017; 4(4):e6-e7. PMC: 5898807. DOI: 10.1016/S2215-0366(17)30089-5. View

15.

Karlawish J . Research involving cognitively impaired adults. N Engl J Med. 2003; 348(14):1389-92. DOI: 10.1056/NEJMsb030172. View

16.

Petersen R, Thomas R, Aisen P, Mohs R, Carrillo M, Albert M . Randomized controlled trials in mild cognitive impairment: Sources of variability. Neurology. 2017; 88(18):1751-1758. PMC: 5409843. DOI: 10.1212/WNL.0000000000003907. View

17.

Sung N, Crowley Jr W, Genel M, Salber P, Sandy L, Sherwood L . Central challenges facing the national clinical research enterprise. JAMA. 2003; 289(10):1278-87. DOI: 10.1001/jama.289.10.1278. View

18.

Rinne J, Brooks D, Rossor M, Fox N, Bullock R, Klunk W . 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010; 9(4):363-72. DOI: 10.1016/S1474-4422(10)70043-0. View

19.

Rabinowitz Y, Gallagher-Thompson D . Recruitment and retention of ethnic minority elders into clinical research. Alzheimer Dis Assoc Disord. 2012; 24 Suppl:S35-41. View